
ABOUT QUOTIENT SCIENCES
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway for small molecule & peptide drug programs. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions and molecules need to become cures, fast. Because humanity needs solutions, fast.
Fully integrated programs from candidate selection through commercial manufacturing.
With an integrated offering of drug substance, drug product development & manufacturing, and clinical testing, Quotient Sciences helps leading pharma and biotech companies worldwide reach their drug program’s milestones as quickly and efficiently as possible. Our capabilities are robust and range from candidate selection, through early and late phase development, through commercial manufacturing.
- Candidate selection – Quotient Sciences helps clients evaluate and quickly identify leading drug candidates, shortening the time it takes to reach the clinic.
- Early phase development – From first-in-human testing to drug product supply for clinical trials, our expertise and capabilities help accelerate drug candidates through proof-of-concept.
- Late phase development – Quotient Sciences expertise in developing patient-centric formulations extends from pilot to commercial scale without sacrificing speed, quality or safety.
Proven expertise to support your unique challenges across a wide range of services.
Quotient Sciences has over 30 years of experience in developing a breadth of formulations across a range of indications and across an array of drug product formats including: oral, inhaled, parenteral & topical. We’ve had the opportunity to work on over 1,500 molecules and possess a depth of expertise in modified release, oral peptides, ADME studies, Radiolabeling, Scintigraphy, Pediatrics and highly potent compounds. Our innovative approach to formulation development is based on our proven track record in early clinical evaluation delivering phase-appropriate formulations across the product development pathway from candidate selection through commercial product launch
Our core services include:
- Drug substance synthesis and manufacturing
- Formulation development
- Clinical trial manufacturing
- Commercial manufacturing
- Clinical pharmacology
- Bioanalysis
- Data sciences
- Drug development consulting
Translational Pharmaceutics®: Shortening development times to reach patients faster.
Quotient Sciences’ proven approach to drug development is driven through our unique Translational Pharmaceutics® platform, an end-to-end integration of activities including drug substance, formulation development, clinical trial manufacturing and clinical testing. Translational Pharmaceutics® has been trusted by leading pharma and biotech companies worldwide to streamline drug development, shortening development times an average of 12 months or more while reducing R&D spend and supply chain complexity. To date, Quotient Sciences’ Translational Pharmaceutics® approach has been used in the development of over 500 global drug programs.
PRECLINICAL & CANDIDATE SELECTION
EARLY PHASE DRUG DEVELOPMENT
PHASE II THROUGH COMMERCIAL MANUFACTURING
CONTACT INFORMATION
Quotient Sciences
Mere Way, Ruddington
Nottingham, NG11 6JS
Phone: +44 (0)115 974 9000
Contact: Erica Fearnley, Executive Director, Strategic Marketing
US & UK LOCATIONS & CONTACT INFORMATION
Quotient Sciences – Nottingham, UK- Global HQ (Early Phase Drug Development & Clinical Testing)
Quotient Sciences – Reading UK (Early Phase Drug Development)
Quotient Sciences – Alnwick, UK (Preclinical to Early Phase Drug Development, Drug Substance)
Quotient Sciences – Edinburgh, UK (Data Sciences)
Quotient Sciences – Garnet Valley, PA USA (Early Phase Drug Development)
Quotient Sciences – Chelsea Parkway, PA USA (Late Stage & Commercial Manufacturing)
Quotient Sciences – Miami, FL USA (Clinical Testing)
Toll free U.S. +1 800 769 3518
Global +44 (0)115 974 9000
ABOUT QUOTIENT SCIENCES CRO & CDMO SERVICES
NEWS
- Quotient Sciences Expands Formulation Development Capabilities To Further Accelerate Drug Development Timelines
- Oxilio's OXL001 Development Program Receives Regulatory Approval
- Quotient Sciences Expands UK Facilities To Support The Delivery Of Translational Pharmaceutics® Programs
- Ensysce Biosciences And Quotient Sciences Announce A Partnership An The Development And Clinical Testing Of Ensysce's PF614-MPAR, A Novel Opioid Designed To Prevent Abuse And Overdose